TREATING SPECIAL POPULATIONS OVERVIEW Tobacco Treatment Smoking Outcomes Co-occurring Disorders Integration Tobacco Prevention READINESS to QUIT in SPECIAL POPULATIONS* Intend to quit in next 6 mo General Population
40% General Psych Outpts 43% Depressed Outpatients Intend to quit in next 30 days 20% 28% 55% Psych. I npatients 24% 41% Methadone Clients 24%
48% 0% 20% Smokers with mental illness or addictive disorders are just as ready to quit smoking as the general population of smokers. 22% 40% 60% 80% 100% * No relationship between psychiatric symptom severity and readiness to quit
RESEARCH on TOBACCO & DEPRESSION Most of the research has been conducted with people with a history of MDD, in freestanding smoking clinics Greater tobacco abstinence with increased psychological support (Hall et al., 1994; Brown et al., 2001) Individuals with recurrent MDD may be especially helped by CBTmood management approaches Individuals with a history of MDD may have more difficulty quitting and more severe withdrawal symptoms than those without MDD TREATING TOBACCO DEPENDENCE in DEPRESSED
SMOKERS Hall et al., 2006. Am J Public Health ABSTINENCE RATES by TREATMENT CONDITION 30% * 7 d ay P P A (% ) 25% 20% * 25% 20% 19% 21% 16% 18%
15% 12% 12% 10% Intervention Control 5% 0% 3 6 12 Month 18 * p<.05 for group comparison
DEPRESSION SEVERITY & TOBACCO TREATMENT OUTCOME NO RELATIONSHIP Depression severity, as measured by the Beck Depression Inventory-II, was unrelated to participants likelihood of quitting smoking Among intervention participants, depression severity was unrelated to their likelihood of accepting cessation counseling and nicotine patch TREATMENT of PSYCHIATRIC INPATIENTS Using the same model...
Tobacco cessation treatment initiated during psychiatric hospitalization 224 patients enrolled Full range of psychiatric diagnoses 79% recruitment rate >80% retention at 18 months Efficacy outcomes thru 18 months still being collected (trial will end August 2010) PI: Prochaska, NIDA K23 DA018691 TREATING SMOKERS with SCHIZOPHRENIA Treatments tailored for smokers with schizophrenia no more effective than standard programs (George et al., 2000)
Atypical antipsychotics associated with greater cessation than typical antipsychotics TWO RCTS of TOBACCO TREATMENT in PATIENTS with SCHIZOPHRENIA Placebo Bupropion Placebo 60% 50% 60% 50% 40% 30%
40% 30% 20% 10% 20% 10% 0% 0% Bupropion End of Tx 6 mo FU End of Tx 6 mo FU George et al. (2002) Evins et al. (2005) VARENICLINE USE with INDIVIDUALS with
SCHIZOPHRENIA Evins et al. (2008): Open-label case series reported 13 of 19 patients (68%) with schizophrenia quit smoking at the end of treatment Two RCTs in process of varenicline use in individuals with schizophrenia (Pfizer & NIDA) DOES ABSTINENCE from TOBACCO CAUSE RECURRENCE of PSYCHIATRIC DISORDERS? Case studies suggesting MDE recurrence after quitting smoking among those with a history of depression
Glassman, 2001: MDE recurrence in 6% (n=2) of those smoking vs. 31% (n=13) of those abstinent Differential loss to follow-up: 5% (n= 2/44) of quitters missing vs. 39% (n= 22/56) of continued smokers Tsoh, 2001: N=308, no difference in rate of MDE among abstinent vs. smoking participants Difference in rate of MDE by depression history: 10% among those with no MDD history vs. 24% if MDD+ Depression is a remitting and relapsing disorder history MENTAL HEALTH OUTCOMES: DEPRESSED SMOKERS TREATED for TOBACCO Among depressed patients who quit smoking: No increase in suicidality
No increase in psych hospitalization Quit: 0% vs Smoking: 1-4% Quit: 0-1% vs. Smoking: 2-3% Comparable improvement in % of days with emotional problems No difference in use of marijuana, stimulants or opiates Less alcohol use among those who quit smoking Prochaska et al., 2008, Am J Public Health
TOBACCO CESSATION & SCHIZOPHRENIA SYMPTOMS Tobacco abstinence (1-wk) not associated with worsening of: attention, verbal learning/memory, working memory, or executive function/inhibition, or clinical symptoms of schizophrenia (Evins et al., 2005) Bupropion: decreased the negative symptoms of schizophrenia (Evins et al. 2005, George et al. 2002) Varenicline: no worsening of clinical symptoms and a trend toward improved cognitive function (Evins et al., 2009) INTEGRATING TOBACCO
TREATMENT within PTSD SERVICES RCT with 66 clients from VA Medical Center Integrated care (IC) Manualized treatment delivered by PTSD clinician and case manager (3-hr training) Behavioral counseling once a week for 5 weeks + 1 follow-up Bupropion, nicotine patch, gum, spray Usual care (UC): referral to VA smoking cessation clinic McFall et al. (2005) Am J Psychiatry INTEGRATING TOBACCO
TREATMENT within PTSD SERVICES Cessation Medication Use Counseling Sessions Attended Integrated Intervention: 94% Usual Care: 64% Integrated Intervention: M=5.5 Usual Care: M=2.6 At all assessments, the odds of abstinence were 5 times greater for integrated care vs. usual care
McFall et al. (2005) Am J Psychiatry SUMMARY: TOBACCO TREATMENT in PSYCHIATRIC PATIENTS In general, currently available interventions show effectiveness Wide range of abstinence rates, with unknown determinants Evidence of deleterious effect on psychiatric symptoms or recurrence is weak Integration into mental health treatment settings increases abstinence rates
TOBACCO CESSATION DURING ADDICTIONS TREATMENT or RECOVERY Meta-analysis of 19 trials 12 in treatment; 7 in recovery Findings: Tobacco Cessation In Treatment Studies: Post treatment abstinence rates were intervention=12% vs. control=3% In Recovery Studies: Post treatment abstinence rates were intervention=38% vs. control=22% No significant effect for tobacco cessation at
long-term follow-up (> 6 months) Prochaska, Delucchi & Hall (2004) JCCP TOBACCO CESSATION DURING ADDICTIONS TREATMENT or RECOVERY Systematic review of 17 studies Smokers with current and past alcohol problems: More nicotine dependent Less likely to quit in their lifetime As able to quit smoking as individuals with no alcohol problems Hughes & Kalman (2006) Drug Alc Dep DOES ABSTINENCE from TOBACCO CAUSE RELAPSE to ALCOHOL and
ILLICIT DRUGS ? At > 6 months follow-up, tobacco treatment with individuals in addictions treatment was associated with a 25% increased abstinence from alcohol and illicit drugs (Prochaska et al., 2004). Caveat: One well done study (N=499) of concurrent versus delayed treatment reported (Joseph et al., 2004): Comparable smoking abstinence rates at 18 months (12.4% versus 13.7%) Lower 6-month prolonged alcohol abstinence rates among those offered concurrent compared to delayed tobacco cessation treatment; NS at 12 and 18-months SUMMARY: TOBACCO TREATMENT for SUBSTANCE ABUSING PATIENTS
In general, currently available interventions show some effectiveness, at least for the short-term Range of abstinence rates, with unknown determinants Weak evidence of deleterious effect on abstinence from illicit drugs and alcohol Disorder specific data may eventually allow better tailoring of treatments PREVENTION Problem of identification and developmental sequence, with a few exceptions:
ADHD ADHD diagnosed prior to initiation of smoking Smoking rates 2 to 3 times higher for adolescents with vs. without ADHD Adults with childhood history of ADHD may have more difficulty in quitting smoking (Humfleet et al., 2005) Children of parents with addiction problems Sons more likely to be recent smokers than the general population (Schukit et al. 2004) PREVENTION Drug Abuse Treatment Settings
Prospective study, N=649 At 12-month follow-up, 13% of the 395 baseline smokers reported quitting smoking and 12% of the 254 baseline nonsmokers reported starting/relapsing to smoking Kohn et al. (2003) Drug Alc Dep Those who deliver mental health care often pride themselves on treating the whole patient, on seeing the big picture, and on not being bound by financial irrationality or by the biases of their culture; yet many fail to treat nicotine dependence. They forget that when their patient dies of a smoking-related disease, their patient has died of a psychiatric illness they failed to treat.
Visceral ectopic fat accumulation, which often occurs with inflammation and type 2 diabetes, causes resistance to insulin action and hepatic necro-inflammation (by Kupffer cell activation) with activation of hepatic stellate cells and increased production of collagen matrix and progression of...
Diamond, Douglas W., and Philip H. Dybvig, 1986, Banking Theory, Deposit Insurance, and Bank Regulation, Journal of Business 59 How to Eliminate Bank Failures Completely怎样完全消除银行倒闭 If we want to avoid the problem of banks blowing up, it is simple: just...
Answer (3) Vladimir is the next driver. He continues the journey on an eight-hour drive to the Belarus border and Brest. He waits until the change in the guards and then drives the car to the checkpoint where he hands...
From the point of view of finding prime implicants, X's (don't cares) are treated as 1's. Essential prime implicant A prime implicant that covers at least one 1 not covered by any other prime implicant (as always). Don't cares (X's)...
Atrial syncytium Ventricular syncytium Fibrous insulator exists between atrium and ventricle (why?) Figure 9-1; Guyton & Hall ... Introduction to Physiology: The Cell and General Physiology Author: Denise Roslonski Last modified by: Julie Rutherford Created Date:
Work begins with a focus on the patient and the current situation, be it diagnosis, survivorship, or the news that the disease cannot be treated. ... Community-Medical Partnerships to address "social determinants of care" ...
Born in Port Lambton, Ontario, Canada, she completed her bachelor's and master's degrees at the University of Toronto and then worked a year at the Rockefeller Institute in New York before returning to the university for her M.D. Michaelis and...
Ready to download the document? Go ahead and hit continue!